McLeod Health

Pegloticase (Krystexxa) Treatment Plan

Patient Name:		DOB:	
Height (cm):	Weight (kg):	Allergies:	
Patient Primary Phone Nu	umber:		
Diagnosis (select one):			
☐ M1A Chron	ic Gout		
☐ Other: ICD 10 Code:	Diagnosis	Description:	
<u>Pre-Medications:</u> **adm	inistered 30 minutes prior to ir	nfusion**	
□ None			
☐ Acetaminophen 650 mg	g PO		
☐ Diphenhydramine: □	ose: ☐ 25 mg ☐ 50 mg	Route: \square PO or \square IVP	
☐ Methylprednisolone: ☐	ose: ☐ 40 mg or ☐ 125 mg	Route: IVP	
Drug Orders:			
• Pegloticase (Krystexxa)	(J2507) 8 mg per 250 mL of So	dium Chloride 0.9% via IV route over 2 hours	once every 2 weeks
• Order Duration: One ye	ar unless otherwise specified (Other:)
Standing Orders:			
• Monitor patient for 1 he	our following each injection.		
	ocol (CPOE-1396) will be activated stopped and physician notified	ted if any hypersensitivity reaction occurs, ind	luding anaphylaxis.
Physician Signature:		Date:	
Physician Name		Phone:	

Approved: 12/2024

Pre-Screening Requirements:

- Uric acid level
- G6PD status

Previous Therapies:

 For new patient referrals, please send history 	and physical and most recent ph	nysician note with completed plan		
• If patient has previously received pegloticase at another facility, please provide last date received:				
If patient has previously received another biologic therapy, please provide the name:				
and the last date received:				
Insurance Information:				
Insurance Plan Name:				
Insurance Identification Number:				
Insurance Customer Service Contact Number:				
Preferred Treatment Location				
☐ McLeod Regional Medical Center (Florence)	☐ McLeod Health Loris	☐ McLeod Health Cheraw		
☐ McLeod Health Seacoast (Little River)	☐ McLeod Health Dillon	☐ McLeod Health Clarendon (Manning)		

Fax completed Treatment Plan to the McLeod Medication Access Team at 843-777-9798. For any questions, please contact our team at medicationaccessteam@mcleodhealth.org.

Approved: 12/2024